Corbus Pharmaceuticals Holdings IncNASDAQ:CRBP
- LAST PRICE42.8000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots40.1000/ 10
- Ask / Lots42.0000/ 11
- Open / Previous Close0.0000 / 42.8000
- Day Range---
- 52 Week Range
- Volume1,099
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRBP |
|---|---|---|
| 09:32 ET | 394 | 41.86 |
| 09:34 ET | 5100 | 41.55 |
| 09:38 ET | 166 | 42 |
| 09:39 ET | 348 | 41.53 |
| 09:41 ET | 1800 | 42 |
| 09:45 ET | 200 | 41.52 |
| 09:56 ET | 100 | 41.975 |
| 09:57 ET | 435 | 41.5376 |
| 10:01 ET | 100 | 41.275 |
| 10:06 ET | 900 | 41.74 |
| 10:12 ET | 100 | 41.58 |
| 10:15 ET | 901 | 42.36 |
| 10:17 ET | 100 | 41.98 |
| 10:24 ET | 400 | 41.88 |
| 10:26 ET | 100 | 41.88 |
| 10:28 ET | 783 | 41.7 |
| 10:32 ET | 278 | 41.84 |
| 10:33 ET | 2800 | 41.94 |
| 10:35 ET | 608 | 42.25 |
| 10:42 ET | 100 | 42.21 |
| 10:46 ET | 200 | 42.145 |
| 10:48 ET | 100 | 42.17 |
| 10:50 ET | 100 | 42.19 |
| 10:51 ET | 2950 | 41.92 |
| 11:00 ET | 2100 | 42 |
| 11:02 ET | 400 | 42.35 |
| 11:04 ET | 2600 | 42.1 |
| 11:06 ET | 120 | 41.985 |
| 11:08 ET | 1800 | 41.92 |
| 11:09 ET | 900 | 42.2 |
| 11:15 ET | 440 | 42.125 |
| 11:20 ET | 100 | 42.095 |
| 11:26 ET | 5890 | 42.29 |
| 11:27 ET | 417 | 42.41 |
| 11:31 ET | 100 | 42.5 |
| 11:42 ET | 3635 | 42.5 |
| 11:44 ET | 1433 | 42.95 |
| 11:45 ET | 416 | 43.16 |
| 11:47 ET | 100 | 43.11 |
| 11:56 ET | 100 | 43.1 |
| 12:02 ET | 100 | 43.17 |
| 12:05 ET | 100 | 43.13 |
| 12:07 ET | 200 | 43.13 |
| 12:09 ET | 938 | 43.34 |
| 12:16 ET | 100 | 43.52 |
| 12:25 ET | 100 | 43.55 |
| 12:27 ET | 550 | 43.645 |
| 12:30 ET | 800 | 43.59 |
| 12:32 ET | 312 | 43.79 |
| 12:36 ET | 200 | 43.77 |
| 12:38 ET | 1969 | 43.5 |
| 12:41 ET | 250 | 43.5154 |
| 12:43 ET | 300 | 43.48 |
| 12:52 ET | 650 | 43.365 |
| 12:56 ET | 600 | 43.195 |
| 12:57 ET | 200 | 43.2 |
| 01:03 ET | 200 | 42.89 |
| 01:06 ET | 700 | 42.78 |
| 01:10 ET | 877 | 42.73 |
| 01:12 ET | 1500 | 43 |
| 01:21 ET | 661 | 42.995 |
| 01:24 ET | 200 | 43.1 |
| 01:26 ET | 100 | 43 |
| 01:30 ET | 100 | 43.01 |
| 01:33 ET | 100 | 42.88 |
| 01:35 ET | 315 | 43.0145 |
| 01:37 ET | 800 | 42.825 |
| 01:39 ET | 900 | 43 |
| 01:50 ET | 141 | 43.35 |
| 02:00 ET | 200 | 43.36 |
| 02:02 ET | 100 | 43.37 |
| 02:06 ET | 100 | 43.43 |
| 02:11 ET | 1233 | 43.58 |
| 02:13 ET | 800 | 43.73 |
| 02:15 ET | 100 | 43.92 |
| 02:22 ET | 225 | 44.18 |
| 02:26 ET | 300 | 44.03 |
| 02:27 ET | 100 | 44.14 |
| 02:31 ET | 126 | 44.18 |
| 02:36 ET | 100 | 44.085 |
| 02:44 ET | 200 | 44.04 |
| 02:45 ET | 100 | 44.21 |
| 02:49 ET | 2577 | 44.31 |
| 02:51 ET | 1100 | 44.07 |
| 02:54 ET | 300 | 44 |
| 02:58 ET | 300 | 44.005 |
| 03:00 ET | 100 | 44 |
| 03:05 ET | 330 | 43.82 |
| 03:12 ET | 145 | 43.92 |
| 03:14 ET | 100 | 43.92 |
| 03:16 ET | 200 | 43.91 |
| 03:18 ET | 1048 | 43.74 |
| 03:23 ET | 200 | 43.615 |
| 03:25 ET | 200 | 43.405 |
| 03:27 ET | 100 | 43.195 |
| 03:30 ET | 300 | 43.19 |
| 03:32 ET | 2672 | 43.335 |
| 03:34 ET | 100 | 43.335 |
| 03:36 ET | 100 | 43.09 |
| 03:38 ET | 400 | 43.02 |
| 03:39 ET | 400 | 43.02 |
| 03:41 ET | 2842 | 43.42 |
| 03:43 ET | 248 | 43.23 |
| 03:45 ET | 1100 | 42.94 |
| 03:48 ET | 3600 | 43.065 |
| 03:50 ET | 1300 | 42.83 |
| 03:52 ET | 4600 | 42.655 |
| 03:54 ET | 9807 | 42.74 |
| 03:56 ET | 2820 | 42.46 |
| 03:57 ET | 2941 | 42.68 |
| 03:59 ET | 2253 | 42.8 |
Today
DJ Corbus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 36 minutes ago by Dow Jones
36 minutes ago by Dow Jones
Jun 1, 2024
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024, from 10:00AM ET on Saturday Jun 01, 2024 by Dow Jones
10:00AM ET on Saturday Jun 01, 2024 by Dow Jones
May 30, 2024
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference, from 8:00AM ET on Thursday May 30, 2024 by Dow Jones
8:00AM ET on Thursday May 30, 2024 by Dow Jones
May 23, 2024
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting, from 5:05PM ET on Thursday May 23, 2024 by Dow Jones
5:05PM ET on Thursday May 23, 2024 by Dow Jones
May 13, 2024
DJ Corbus Pharmaceuticals Initiated at Outperform by RBC Capital, from 7:34AM ET on Monday May 13, 2024 by Dow Jones
7:34AM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 457.4M | -6.1x | --- |
Annexon Inc | 446.4M | -3.3x | --- |
Korro Bio Inc | 475.7M | -1.2x | --- |
Nkarta Inc | 478.5M | -2.9x | --- |
Neurogene Inc | 488.1M | -8.2x | --- |
Cabaletta Bio Inc | 491.9M | -5.9x | --- |
Company Information
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Contact Information
- Headquarters
- 500 River Ridge DriveNORWOOD, MA, United States 02062
- Phone
- 617-963-0103
- Fax
- ---
Executives
- Independent Director
- Alan Holmer
- Chief Executive Officer, Director
- Yuval Cohen
- Chief Financial Officer
- Sean Moran
- Chief Medical Officer
- Dominic Smethurst
- Independent Director
- Anne Altmeyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $457.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.52 |
EPS | $-6.97 |
Book Value | $-1.56 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
